Orexigen Therapeutics Stock Price, News & Analysis (NASDAQ:OREX)

$1.23 -0.03 (-2.38 %)
(As of 12/15/2017 10:42 AM ET)
Previous Close$1.26
Today's Range$1.15 - $1.26
52-Week Range$1.15 - $5.70
Volume309,800 shs
Average Volume314,813 shs
Market Capitalization$20.92 million
P/E RatioN/A
Dividend YieldN/A
Beta2.3

About Orexigen Therapeutics (NASDAQ:OREX)

Orexigen Therapeutics logoOrexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.

Receive OREX News and Ratings via Email

Sign-up to receive the latest news and ratings for OREX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:OREX
CUSIP68616410
Phone858-875-8600

Debt

Debt-to-Equity Ratio-2.75%
Current Ratio2.00%
Quick Ratio1.71%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$33.71 million
Price / Sales0.61
Cash FlowN/A
Price / CashN/A
Book Value$3.91 per share
Price / Book0.31

Profitability

Trailing EPS($9.71)
Net Income$-24,520,000.00
Net Margins-192.65%
Return on Equity-824.15%
Return on Assets-68.53%

Miscellaneous

Employees132
Outstanding Shares16,600,000

Orexigen Therapeutics (NASDAQ:OREX) Frequently Asked Questions

What is Orexigen Therapeutics' stock symbol?

Orexigen Therapeutics trades on the NASDAQ under the ticker symbol "OREX."

How were Orexigen Therapeutics' earnings last quarter?

Orexigen Therapeutics, Inc. (NASDAQ:OREX) issued its quarterly earnings data on Monday, November, 13th. The biopharmaceutical company reported ($1.35) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($2.13) by $0.78. The biopharmaceutical company earned $18.90 million during the quarter, compared to the consensus estimate of $24.20 million. Orexigen Therapeutics had a negative net margin of 192.65% and a negative return on equity of 824.15%. The firm's revenue was up 170.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.12 EPS. View Orexigen Therapeutics' Earnings History.

Who are some of Orexigen Therapeutics' key competitors?

Who are Orexigen Therapeutics' key executives?

Orexigen Therapeutics' management team includes the folowing people:

  • Patrick J. Mahaffy, Independent Chairman of the Board (Age 54)
  • Michael A. Narachi, President, Chief Executive Officer, Director (Age 57)
  • Jason A. Keyes, Chief Financial Officer, Senior Vice President (Age 46)
  • Thomas R. Cannell, Chief Operating Officer, Executive Vice President, President - Global Commercial Products (Age 55)
  • Thomas P. Lynch, Executive Vice President, General Counsel, Secretary (Age 50)
  • Peter Flynn Ph.D., Senior Vice President, Head - Development, Regulatory Affairs and Safety (Age 43)
  • Louis C. Bock, Independent Director (Age 52)
  • Brian H. Dovey, Independent Director (Age 75)
  • David J. Endicott, Independent Director (Age 52)
  • Peter K. Honig M.D. M.P.H., Independent Director (Age 60)

How do I buy Orexigen Therapeutics stock?

Shares of Orexigen Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Orexigen Therapeutics' stock price today?

One share of Orexigen Therapeutics stock can currently be purchased for approximately $1.23.

How big of a company is Orexigen Therapeutics?

Orexigen Therapeutics has a market capitalization of $20.92 million and generates $33.71 million in revenue each year. The biopharmaceutical company earns $-24,520,000.00 in net income (profit) each year or ($9.71) on an earnings per share basis. Orexigen Therapeutics employs 132 workers across the globe.

How can I contact Orexigen Therapeutics?

Orexigen Therapeutics' mailing address is 3344 N. TORREY PINES CT. SUITE 200, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-875-8600 or via email at [email protected]


MarketBeat Community Rating for Orexigen Therapeutics (OREX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  173 (Vote Outperform)
Underperform Votes:  173 (Vote Underperform)
Total Votes:  346
MarketBeat's community ratings are surveys of what our community members think about Orexigen Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Orexigen Therapeutics (NASDAQ:OREX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AHoldHold
Consensus Rating Score: N/AN/A2.002.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/A$1.50$1.50
Price Target Upside: N/AN/A182.91% upside182.91% upside

Orexigen Therapeutics (NASDAQ:OREX) Consensus Price Target History

Price Target History for Orexigen Therapeutics (NASDAQ:OREX)

Orexigen Therapeutics (NASDAQ:OREX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/16/2016Leerink SwannLower Price TargetMarket Perform$2.00 -> $1.00N/AView Rating Details
3/16/2016Piper Jaffray CompaniesDowngradeOverweight -> Neutral$5.00 -> $2.00N/AView Rating Details
3/16/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
2/29/2016J P Morgan Chase & CoDowngradeOverweight -> NeutralN/AView Rating Details
2/29/2016Royal Bank of CanadaDowngradeOutperform -> Sector Perform$5.00 -> $1.00N/AView Rating Details
12/16/2015WallachBeth CapitalDowngradeBuy -> HoldN/AView Rating Details
(Data available from 12/15/2015 forward)

Earnings

Orexigen Therapeutics (NASDAQ:OREX) Earnings History and Estimates Chart

Earnings by Quarter for Orexigen Therapeutics (NASDAQ:OREX)

Orexigen Therapeutics (NASDAQ OREX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017Q3 2017($2.13)($1.35)$24.20 million$18.90 millionViewN/AView Earnings Details
8/8/2017Q2 2017($2.40)($1.82)$20.00 million$23.36 millionViewListenView Earnings Details
5/9/2017Q1 2017($2.60)($4.67)$20.00 million$19.10 millionViewListenView Earnings Details
11/3/2016Q316($2.24)$1.12$8.17 million$7.00 millionViewN/AView Earnings Details
8/4/2016Q216($1.47)($1.73)$6.88 million$7.79 millionViewListenView Earnings Details
5/4/2016Q116($0.17)($0.15)$7.78 million$5.00 millionViewListenView Earnings Details
2/26/2016Q415($0.08)($0.12)$14.07 million$4.90 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.09)$12.17 million$10.00 millionViewListenView Earnings Details
8/6/2015Q215($0.17)($0.18)$4.92 million$5.20 millionViewListenView Earnings Details
5/8/2015Q115($0.16)($0.14)$7.28 million$4.36 millionViewListenView Earnings Details
11/10/2014Q3($0.13)$0.09$8.93 million$30.90 millionViewListenView Earnings Details
8/7/2014Q2($0.21)($0.21)$51.80 million$0.86 millionViewListenView Earnings Details
5/8/2014Q1($0.20)($0.23)$0.93 million$0.86 millionViewListenView Earnings Details
3/12/2014Q4($0.19)($0.21)$900.00 million$857.00 millionViewListenView Earnings Details
11/12/2013Q3($0.18)($0.19)$0.80 million$0.86 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.19)($0.19)$0.90 millionViewListenView Earnings Details
3/13/2013Q4 2012($0.44)($0.41)$0.91 million$0.86 millionViewListenView Earnings Details
11/7/2012Q312($0.30)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Orexigen Therapeutics (NASDAQ:OREX) Earnings Estimates

Current Year EPS Consensus Estimate: $-10.08 EPS
Next Year EPS Consensus Estimate: $-6.76 EPS

Dividends

Dividend History for Orexigen Therapeutics (NASDAQ:OREX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Orexigen Therapeutics (NASDAQ OREX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.30%
Institutional Ownership Percentage: 34.69%
Insider Trades by Quarter for Orexigen Therapeutics (NASDAQ:OREX)
Insider Trades by Quarter for Orexigen Therapeutics (NASDAQ:OREX)

Orexigen Therapeutics (NASDAQ OREX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/19/2016Stephen A. MogliaVPSell800$1.96$1,568.00View SEC Filing  
12/2/2014Heather D TurnerSVPSell22,643$6.00$135,858.00View SEC Filing  
11/25/2014Heather D TurnerSVPSell31,388$5.83$182,992.04View SEC Filing  
11/18/2014Louis C BockDirectorBuy1,325$5.58$7,393.50View SEC Filing  
11/12/2014Louis C BockDirectorBuy27,052$5.57$150,679.64View SEC Filing  
9/22/2014Heather D TurnerVPSell300,000$4.47$1,341,000.00View SEC Filing  
9/15/2014Joseph P HaganVPBuy5,000$4.69$23,450.00View SEC Filing  
9/15/2014Michael NarachiCEOBuy50,000$4.78$239,000.00View SEC Filing  
7/31/2013Joseph P HaganInsiderSell12,000$7.80$93,600.00View SEC Filing  
7/26/2013Joseph P HaganInsiderSell10,000$7.40$74,000.00View SEC Filing  
7/25/2013Preston KlassenSVPSell71,229$7.16$509,999.64View SEC Filing  
5/28/2013Joseph P HaganInsiderSell28,000$7.00$196,000.00View SEC Filing  
5/28/2013Preston KlassenSVPSell28,771$7.21$207,438.91View SEC Filing  
1/15/2013Mark D BoothInsiderSell22,315$6.67$148,841.05View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Orexigen Therapeutics (NASDAQ OREX) News Headlines

Source:
DateHeadline
Comparing Orexigen Therapeutics (OREX) and MacroGenics (MGNX)Comparing Orexigen Therapeutics (OREX) and MacroGenics (MGNX)
www.americanbankingnews.com - December 11 at 9:52 PM
Implied Volatility Surging for Orexigen (OREX) Stock OptionsImplied Volatility Surging for Orexigen (OREX) Stock Options
finance.yahoo.com - December 8 at 10:16 AM
Is Orexigen Therapeutics Inc (OREX) An Industry Laggard Or Leader?Is Orexigen Therapeutics Inc (OREX) An Industry Laggard Or Leader?
finance.yahoo.com - December 1 at 5:35 PM
Ophthotech (OPHT) vs. Orexigen Therapeutics (OREX) Head to Head AnalysisOphthotech (OPHT) vs. Orexigen Therapeutics (OREX) Head to Head Analysis
www.americanbankingnews.com - November 28 at 5:38 AM
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Merck KGaA, Darmstadt ... - PR Newswire (press release)Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Merck KGaA, Darmstadt ... - PR Newswire (press release)
www.prnewswire.com - November 15 at 7:11 AM
Earnings Reaction History: Orexigen Therapeutics, Inc., 62.5% Follow-Through Indicator, 7.7% Sensitive - NasdaqEarnings Reaction History: Orexigen Therapeutics, Inc., 62.5% Follow-Through Indicator, 7.7% Sensitive - Nasdaq
www.nasdaq.com - November 15 at 7:11 AM
Orexigen Therapeutics Announces Third Quarter 2017 Financial ... - PR Newswire (press release)Orexigen Therapeutics Announces Third Quarter 2017 Financial ... - PR Newswire (press release)
www.prnewswire.com - November 15 at 7:11 AM
What Does Orexigen Therapeutics Inc’s (OREX) Share Price Indicate?What Does Orexigen Therapeutics Inc’s (OREX) Share Price Indicate?
finance.yahoo.com - November 15 at 7:11 AM
Orexigen Therapeutics, Inc. (OREX) Announces Quarterly  Earnings Results, Beats Expectations By $0.78 EPSOrexigen Therapeutics, Inc. (OREX) Announces Quarterly Earnings Results, Beats Expectations By $0.78 EPS
www.americanbankingnews.com - November 14 at 10:30 AM
BRIEF-Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, DarmstadtBRIEF-Orexigen Therapeutics announces commercialization and distributorship agreement with Merck KGaA, Darmstadt
www.reuters.com - November 14 at 6:35 AM
Orexigen Therapeutics (OREX) CEO Michael Narachi on Q3 2017 Results - Earnings Call TranscriptOrexigen Therapeutics' (OREX) CEO Michael Narachi on Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 14 at 6:35 AM
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Merck KGaA, Darmstadt, Germany for Contrave in Latin AmericaOrexigen Therapeutics Announces Commercialization and Distributorship Agreement with Merck KGaA, Darmstadt, Germany for Contrave in Latin America
finance.yahoo.com - November 14 at 6:35 AM
Orexigen Therapeutics Announces Third Quarter 2017 Financial ResultsOrexigen Therapeutics Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 14 at 6:34 AM
Orexigen reports 3Q lossOrexigen reports 3Q loss
finance.yahoo.com - November 14 at 6:34 AM
Edited Transcript of OREX earnings conference call or presentation 13-Nov-17 10:00pm GMTEdited Transcript of OREX earnings conference call or presentation 13-Nov-17 10:00pm GMT
finance.yahoo.com - November 14 at 6:34 AM
 Analysts Expect Orexigen Therapeutics, Inc. (OREX) to Post -$2.13 Earnings Per Share Analysts Expect Orexigen Therapeutics, Inc. (OREX) to Post -$2.13 Earnings Per Share
www.americanbankingnews.com - November 1 at 1:54 PM
Orexigen Therapeutics to Provide Business Update and Discuss Third Quarter 2017 Financial Results on November 13 ... - PR Newswire (press release)Orexigen Therapeutics to Provide Business Update and Discuss Third Quarter 2017 Financial Results on November 13 ... - PR Newswire (press release)
www.prnewswire.com - November 1 at 7:18 AM
Orexigen Therapeutics to Provide Business Update and Discuss Third Quarter 2017 Financial Results on November 13, 2017Orexigen Therapeutics to Provide Business Update and Discuss Third Quarter 2017 Financial Results on November 13, 2017
finance.yahoo.com - November 1 at 7:18 AM
Orexigen Therapeutics, Inc. (OREX) Set to Announce Earnings on WednesdayOrexigen Therapeutics, Inc. (OREX) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - October 25 at 8:02 AM
Orexigen Therapeutics (OREX) Presents At 2017 BIO Investor Forum - SlideshowOrexigen Therapeutics (OREX) Presents At 2017 BIO Investor Forum - Slideshow
seekingalpha.com - October 19 at 7:13 AM
BRIEF-Orexigen announces favorable decision from U.S. court in patent litigation, confirming exclusivity for Contrave through 2030BRIEF-Orexigen announces favorable decision from U.S. court in patent litigation, confirming exclusivity for Contrave through 2030
www.reuters.com - October 14 at 6:32 AM
 Brokerages Expect Orexigen Therapeutics, Inc. (OREX) Will Post Earnings of -$2.13 Per Share Brokerages Expect Orexigen Therapeutics, Inc. (OREX) Will Post Earnings of -$2.13 Per Share
www.americanbankingnews.com - October 13 at 4:36 PM
Orexigen Therapeutics to Provide Business Update at the 2017 BIO Investor ForumOrexigen Therapeutics to Provide Business Update at the 2017 BIO Investor Forum
finance.yahoo.com - October 13 at 7:50 AM
ETFs with exposure to Orexigen Therapeutics, Inc. : October 11, 2017ETFs with exposure to Orexigen Therapeutics, Inc. : October 11, 2017
finance.yahoo.com - October 12 at 7:55 AM
Orexigen Therapeutics, Inc. (OREX) Lowered to Hold at Zacks Investment ResearchOrexigen Therapeutics, Inc. (OREX) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - October 10 at 12:40 PM
Before You Buy Orexigen Therapeutics Inc’s (OREX), You Should Consider ThisBefore You Buy Orexigen Therapeutics Inc’s (OREX), You Should Consider This
finance.yahoo.com - October 5 at 7:15 PM
Orexigens (OREX) Contrave Sales Improving on Promotions - NasdaqOrexigen's (OREX) Contrave Sales Improving on Promotions - Nasdaq
www.nasdaq.com - September 30 at 5:46 PM
Orexigen Therapeutics Launches Next Stage of a Dynamic Campaign to Educate Consumers About Contrave®Orexigen Therapeutics Launches Next Stage of a Dynamic Campaign to Educate Consumers About Contrave®
finance.yahoo.com - September 29 at 5:39 PM
Orexigen Therapeutics (OREX) Presents At Cantor Fitzgerald Global Healthcare Conference - SlideshowOrexigen Therapeutics (OREX) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 28 at 7:26 PM
BRIEF-Orexigen Therapeutics sees 2017 net sales $85 mln to $100 mln - presentation slides‍BRIEF-Orexigen Therapeutics sees 2017 net sales $85 mln to $100 mln - presentation slides‍
www.reuters.com - September 28 at 1:50 AM
Orexigen Therapeutics to Provide Business Update at the 2017 ... - PR Newswire (press release)Orexigen Therapeutics to Provide Business Update at the 2017 ... - PR Newswire (press release)
www.prnewswire.com - September 14 at 8:50 AM
Orexigen Therapeutics to Provide Business Update at the 2017 Cantor Fitzgerald Global Healthcare ConferenceOrexigen Therapeutics to Provide Business Update at the 2017 Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 14 at 8:50 AM
Orexigen Therapeutics (OREX) versus CLEMENTIA PHARM (CMTA) Critical ContrastOrexigen Therapeutics (OREX) versus CLEMENTIA PHARM (CMTA) Critical Contrast
www.americanbankingnews.com - September 10 at 4:12 AM
Orexigen Therapeutics (OREX) Presents At 2017 Wells Fargo Healthcare Conference - SlideshowOrexigen Therapeutics (OREX) Presents At 2017 Wells Fargo Healthcare Conference - Slideshow
seekingalpha.com - September 9 at 7:05 AM
ETFs with exposure to Orexigen Therapeutics, Inc. : September 7, 2017ETFs with exposure to Orexigen Therapeutics, Inc. : September 7, 2017
finance.yahoo.com - September 8 at 6:51 AM
Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017Orexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017
finance.yahoo.com - August 26 at 8:04 AM
Orexigen Therapeutics, Inc. (OREX) Issues  Earnings ResultsOrexigen Therapeutics, Inc. (OREX) Issues Earnings Results
www.americanbankingnews.com - August 9 at 5:22 PM
Orexigen Therapeutics, Inc. 2017 Q2 - Results - Earnings Call SlidesOrexigen Therapeutics, Inc. 2017 Q2 - Results - Earnings Call Slides
seekingalpha.com - August 9 at 6:08 AM
Orexigen Therapeutics Announces Second Quarter 2017 Financial ResultsOrexigen Therapeutics Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 9 at 6:08 AM
Orexigen reports 2Q lossOrexigen reports 2Q loss
finance.yahoo.com - August 9 at 6:08 AM
Edited Transcript of OREX earnings conference call or presentation 8-Aug-17 9:00pm GMTEdited Transcript of OREX earnings conference call or presentation 8-Aug-17 9:00pm GMT
finance.yahoo.com - August 9 at 6:08 AM
Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Cheplapharm Arzneimittel ... - PR Newswire (press release)Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Cheplapharm Arzneimittel ... - PR Newswire (press release)
www.prnewswire.com - August 7 at 8:13 AM
Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Cheplapharm Arzneimittel GmbH for Mysimba™ in Germany, France and AustriaOrexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Cheplapharm Arzneimittel GmbH for Mysimba™ in Germany, France and Austria
finance.yahoo.com - August 7 at 8:13 AM
-$2.40 EPS Expected for Orexigen Therapeutics, Inc. (NASDAQ:OREX) This Quarter-$2.40 EPS Expected for Orexigen Therapeutics, Inc. (NASDAQ:OREX) This Quarter
www.americanbankingnews.com - July 31 at 12:28 PM
Orexigen Therapeutics Announces Expansion of Distributorship Agreement with Biologix FZCO for Contrave ... - PR Newswire (press release)Orexigen Therapeutics Announces Expansion of Distributorship Agreement with Biologix FZCO for Contrave ... - PR Newswire (press release)
www.prnewswire.com - July 28 at 6:33 AM
Orexigen Therapeutics Announces Expansion of Distributorship Agreement with Biologix FZCO for Contrave® (naltrexone HCl / bupropion HCl extended release) to EgyptOrexigen Therapeutics Announces Expansion of Distributorship Agreement with Biologix FZCO for Contrave® (naltrexone HCl / bupropion HCl extended release) to Egypt
finance.yahoo.com - July 27 at 6:05 AM
Orexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2017 Financial Results on August 8, 2017Orexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2017 Financial Results on August 8, 2017
finance.yahoo.com - July 26 at 6:08 AM
15 Biggest Mid-Day Gainers For Thursday | Benzinga - Benzinga15 Biggest Mid-Day Gainers For Thursday | Benzinga - Benzinga
www.benzinga.com - July 21 at 5:49 AM
Vivus Settlement Could Clue In Orexigen Investors - Seeking AlphaVivus Settlement Could Clue In Orexigen Investors - Seeking Alpha
seekingalpha.com - July 21 at 5:49 AM
Martin Shkreli made gay investor uncomfortable with sex talkMartin Shkreli made gay investor uncomfortable with sex talk
finance.yahoo.com - July 19 at 1:08 AM

SEC Filings

Orexigen Therapeutics (NASDAQ:OREX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Orexigen Therapeutics (NASDAQ:OREX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Orexigen Therapeutics (NASDAQ OREX) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.